Keywords
How to Cite
Abstract
Using appropriate electrophoretic techniques, low (LMWM), intermediate (IMWM), high (HMWM) and ultra-high (UHMWM) molecular weight mul-timers can be estimated. The aim of the study was to determine whether the multimeric profile obtained by agarose gel electro-phoresis followed by immunofixation in a semi-automated s (Hydragel 5) and by the reference method are comparable. 24 samples were analyzed: four from patients with acquired von Willebrand syndrome (AVWS) sec-ondary to myeloproliferative syndrome with throm-bocytosis (MPS-T), 18 from patients with VWD of different types, and 2 from patients with thrombotic thrombocytopenic purpura (TTP).The measurement was performed with two different methodologies: Multimers by semiautomatic method: SDS-Aga-rose electrophoresis followed by immunofixation using Hydragel 5 von Willebrand Multimers kit on the Hydrasys 2 instrument (Sebia), analyzed by the Phoresis program. Multimers by reference method: SDS-agarose electrophoresis followed by immunofixation using polyclonal antibodies: rabbit anti-human VWF, pig-grown/biotinylated rabbit IgG, avidin perox-idase and revealed with 4Cl-1-naphthol. Multim-eric profile: analyzed by ImageQuant TL 8.1 (GE Healthcare).AVWS samples showed decreased HMWM, while type 1 VWD samples showed a normal multimeric profile. UHMWM were detected in the TTP sam-ples.Considering the VWD type 2 samples, 2A, 2B and 2M, a good agreement was obtained between both methods.The semi-automated method seems to be useful and appropriate for screening VWF multimeric profiles in hemostasis clinical laboratories analyzed by high-ly specialized staff in the diagnosis of VWD.
References
Woods AI, Blanco AN, Kempfer AC y col. Factor von Willebrand y Enfermedad de von Willebrand: nuevos enfoques diagnósticos. Acta Bioquím Clín Latinoam. 2016;50:273-289.
Stockschlaeder M, Schneppenheim R, Budde U. Up-date on von Willebrand factor multimers: focus on high molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis. 2014, 25:206-216.
James PD, Connell NT, Ameer B y col. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021; 12:280-300.
Ledford-Kraemer MR. Analysis of von Willebrand factor structure by multimer analysis. Am J Hematol. 2010;85(7):510-514.
Favaloro EJ, Pasalic L, Curnow J. Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology. 2016;48:303-318.
Oliver S, Edwin Lau KK, Chapman K, Favaloro EJ. Laboratory Testing for Von Willebrand Factor Multi-mers. Methods Mol Biol. 2017;1646:495-511.
Favaloro EJ, Oliver S. Evaluation of a new commercial von Willebrand factor multimer assay. Haemophilia. 2017;23:e373-e7.
Farías C, Kempfer AC, Blanco A, Woods A, Lazzari MA. Visualization of the multimeric structure of von Willebrand factor by immunoenzymatic stain using avidin-peroxidase complex instead of avidin-biotin peroxidase complex. Thromb Res. 1989;53(5):513-518.
Woods AI, Paiva J, Primrose DM, Blanco AN, Sán-chez-Luceros A. Type 2A and 2M von Willebrand Dis-ease: Differences in Phenotypic Parameters According to the Affected Domain by Disease-Causing Variants and Assessment of Pathophysiological Mechanisms. Semin Thromb Hemost. 2021;47:862-874.
Woods AI, Kempfer AC, Paiva J y col. Phenotypic Parameters in Genotypically Selected Type 2B von Willebrand Disease Patients: A Large, Single-Center Experience Including a New Novel Mutation. Semin Thromb Hemost. 2017;43: 92-100.
Pikta M, Zemtsovskaja G, Bautista H y col. Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multi-mers. J Clin Lab Anal. 2018;32:e22416.
Franchini M, Mannucci PM. Acquired von Willebrand Syndrome: focused for hematologists. Haematologica. 2020;105:2032-2037.
Federici AB, Mannucci PM, CastamanG y col. Clin-ical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009;113:526-534.
Oliver S, Vanniasinkam T, Mohammed S, Vong R, Favaloro EJ. Semi- automated von Willebrand factor multimer assay for von Willebrand disease: Further validation, benefits and limitations. Int J Lab Hematol. 2019;41:762-771.
Bowyer AE, Goodfellow KJ, Seidel H y col. Evaluation of a semi-automated von Willebrand factor multim-er assay, the Hydragel 5 von Willebrandmultimer, by two European Centers. Res Pract Thromb Haemost. 2018;2:790-799.
Woods AI, Paiva J, Primrose DM, Blanco AN, San-chez-Luceros A. Von Willebrand disease type 2M: Correlation between genotype and phenotype: Comment from Woods et al. J Thromb Haemost. 2022;20:1022-1023
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar